ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

The Clinical Manifestations And Treatment Of Von Willebrand’s Disease (Pseudohemophilia)

Updated on February 4, 2014

Von Willebrand’s disease


Clinical Manifestations

Von Willebrand’s disease (vWD) is a primary vascular hemostatic defect, transmitted as an autosomal dominant, affecting both sexes. Next to hemophilia, this is the most frequent inherited hemostatic defect. The basic defect is reduction of the amount of subendothelial factor VIII: vWF polymers or the presence of abnormal or inadequately polymerized subendothelial factor VIII:vWF. Normal vWF contains multimers of varying molecular sizes ranging from 850,000 to 12 million Daltons. The defective factor VIII:vWF leads to impairment of platelet adhesion to sites of vascular injury. Depending on the genetic defect, the disease has been divided into three types.

  1. Type I (or classic disease): Decreased release of factor VIII:vWF from endothelial cell. This is the common form.
  2. Type II A: Defective endothelial cell polymerization of factor VIII:vWF sub-units.
  3. Type II B: Abnormal synthesis of factor VIII:vWF polymers by endothelial cells.

Clinical features

These are similar to that of ITP, i.e excessive post-traumatic bleeding, menorrhagia and mucosal bleeding, especially from the nose, gums, gastrointestinal tract and genitourinary tract. Bleeding time is prolonged. Platelet counts are norla in Types I and II A, but may be moderately decreased in IIB. In those with factor VIII:C levels below 1% of normal, manifestations of a coagulation defect may also be prominent. Bleeding manifestations are most marked in homozygous type IIA vWD which is rare.

Diagnosis of the specific defect of factor VIII:vWF is made by electrophoresis. Another in vitro test is to determine the capacity of plasma to aggregate platelets in the presence of the antibiotic-ristocetin. Ristocetin partially neutralizes negative charges on platelet surfaces and thus enables the negatively charged factor VIII: vWF polymers to induce platelet aggregation. This phenomenon is called ristocetin cofactor activity. Ristocetin cofactor activity is diminished in types I and II A disease.

In patients with type I and IIA vWD, the diminution of ristocetin cofactor activity correlates with the defective platelet adhesion to subendothelium in vitro. But in type II B disease, this is not so. In type II B, the factor VIII: vWF polymers are abnormally formed and these are incapable of inducing platelets to adhere to vascular endothelium. But even in the presence of small amounts of ristocetin, these abnormal polymers present in platelet poor plasma attach to platelets and induce aggregation in vitro.

In homozygous type II A vWD, patients with severe bleeding tendency, endothelial polymerization of factor VIII: vWF monomers is defective and only small factor VIII: vWF polymers are present in plasma. In these patients, bleeding time is prolonged and plasma levels of factor VIII: vWF antigen, ristocetin cofactor activity, and factor VIII:C are extremely low. The majority of cases of vWD being heterozygous, have only mild bleeding tendency.

Factor VIII:C is also reduced in the plasma of majority of patients with vWD. Unlike hemophilia in which the synthesis of factor VIII:C is diminished, in vWD, though factor VIII:C is synthesized, it is not transported effectively in the systemic circulation without adequate levels of polymerized factor VIII: vWF. Further, factor VIII:C molecules which enter the circulation unbound to VIII”vWF polymers are rapidly removed.

Treating Von Willebrand’s disease



Cryoprecipitate infusions arrest bleeding promptly and these are employed to arrest bleeding episodes and to prepare the patient for surgery. The largest factor VIII:vWF polymers in the cryoprecipitate get deposited on the injured subendothelial surface and this favours platelet adhesion and hemostasis. The therapeutic effect lasts only for 4 hours and hence cryoprecipitate has to be repeated. Lyophilised factor VIII preparations are not as effective as cryoprecipitate as they do not contain the largest plasma factor VIII:vWF polymer forms.

In type I vWD where synthesis of factor VIII:vWF within the endothelial cells is normal, infusion of deamino-8-D arginine vasopression (DDAVP) causes release of VIII:vWF polymers from endothelial cells- DDAVP attaches itself to vasopressin receptors on the endothelial cells and helps in releasing factor VIII:vWF polymers. In heterozygous type IIA and IIB and homozygous type II A vWD, DDAVP is not very effective.

© 2014 Funom Theophilus Makama


    0 of 8192 characters used
    Post Comment

    No comments yet.


    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

    Show Details
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)